Shanghai's Harbour BioMed in $81 Million Deal for Two HanAll Biologic Drugs

Harbour BioMed, a China-US biopharma, will collaborate with Korea 's HanAll Biopharma to develop two of HanAll's novel biologics in Greater China. HanAll will receive up to $81 million in a combination of upfront and milestone payments, plus royalties. The two HanAll biologics are aimed at autoimmune and inflammatory diseases. Harbour was formed in late 2016, when the company raised $50 million in initial capital and acquired Harbour Antibodies BV, a Dutch company with two proprietary transgenic mouse platforms. More details.... Share this with colleagues: // //